Obrist R
Departement Innere Medizin, Universität, Kantonsspital Basel.
Helv Chir Acta. 1990 Jan;56(5):683-8.
Recombinant cytokines are available for clinical evaluation since several years. They are expected to have novel effects with fewer side effects than conventional cytostatics. Until now interferon alpha has been registered for Kaposi's sarcoma and hairy cell leukemia. Further indications will follow. Hemopoietic growth factors will have a major impact, as no doubt exists about their effectiveness, but their indications need to be defined more thoroughly. Many substances like interleukin 2, tumor necrosis factor and interleukin 1 are currently at a purely experimental stage.
重组细胞因子已经可以用于临床评估数年了。它们有望产生新的效果，且副作用比传统细胞抑制剂更少。到目前为止，α干扰素已被批准用于治疗卡波西肉瘤和毛细胞白血病。更多的适应症将会出现。造血生长因子将产生重大影响，因为它们的有效性毋庸置疑，但它们的适应症需要更全面地确定。许多物质，如白细胞介素2、肿瘤坏死因子和白细胞介素1，目前仍处于纯粹的实验阶段。
